Patents by Inventor Frederic Revah

Frederic Revah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF STIMULATING NERVE REGENERATION
    Publication number: 20020071828
    Abstract: A method used to stimulate neural regeneration can be applied to peripheral nerves as well as nerves of the central nervous system, especially of the spinal cord. The invention notably employs a system including a biocompatible cuff, into which a system of expression of a neurotrophic factor is inserted.
    Type: Application
    Filed: September 23, 1999
    Publication date: June 13, 2002
    Inventors: PASCAL PEULVE, FREDERIC REVAH, MARC TADIE
  • RECOMBINANT ADENOVIRUSES CODING FOR GLIAL-DERIVED CELL NEUROTROPHIC FACTOR (GDNF)
    Publication number: 20020031493
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for glial-derived neurotrophic factor (GDNF), preparation thereof, and use thereof for treating and/or preventing degenerative neurological diseases.
    Type: Application
    Filed: August 1, 1997
    Publication date: March 14, 2002
    Applicant: RHONE-POULENC RORER S.A.
    Inventors: PHILIPPE HORELLOU, JACQUES MALLET, MICHEL PERRICAUDET, FREDERIC REVAH, EMMANUELLE VIGNE
  • ADENOVIRUS COMPRISING A GENE CODING FOR GLUTATHIONE PEROXIDASE
    Publication number: 20010029249
    Abstract: The present invention relates to a defective adenovirus comprising at least a DNA sequence coding for all or an active part of glutathione peroxidase or a derivative thereof. It also relates to their utilisation in therapy and to the corresponding pharmaceutical compositions.
    Type: Application
    Filed: May 1, 1997
    Publication date: October 11, 2001
    Inventors: MARTINE BARKATS, JACQUES MALLET, FREDERIC REVAH
  • Recombinant adenoviruses coding for glial-derived neurotrophic factor (GDNF)
    Patent number: 6245330
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for glial-derived neurotrophic growth factor (GDNF) are provided. The recombinant adenoviruses are useful in a method of expressing GDNF in a cell, wherein the cell is present in a mammal suffering from Parkinson's disease, comprising infecting said cell with a replication-defective recombinant adenovirus comprising a DNA sequence encoding GDNF operably linked to a promoter by administering the adenovirus into cells of the central nervous system. The recombinant adenoviruses of the invention are also useful in a method of treating Parkinson's disease comprising administering into cells of the central nervous system of a mammal suffering therefrom a replication defective recombinant adenovirus comprising ITRs, an encapsidation sequence and a DNA sequence encoding GDNF operably linked to a promoter, wherein the adenovirus E1 gene is non-functional and GDNF is expressed at a level that provides a therapeutic effect.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: June 12, 2001
    Assignee: Aventis Pharma S.A.
    Inventors: Philippe Horellou, Jacques Mallet, Michel Perricaudet, Frédéric Revah, Emmanuelle Vigne
  • Pharmaceutical compositions and their use, namely for the treatment of neurodegenerative diseases
    Patent number: 6140112
    Abstract: The present invention pertains to the use of compounds affecting the activity of transcription factors for the preparation of a pharmaceutical composition for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: April 25, 1996
    Date of Patent: October 31, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Jacques Mallet, Frederic Revah, Jean-Jacques Robert